Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $10.00 by Analysts at KeyCorp

Recursion Pharmaceuticals (NASDAQ:RXRX - Free Report) had its price objective cut by KeyCorp from $12.00 to $10.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Separately, Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $8.75.

Recursion Pharmaceuticals Price Performance

Shares of RXRX traded down $0.23 during trading hours on Wednesday, hitting $7.26. 12,980,114 shares of the company were exchanged, compared to its average volume of 17,259,441. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a market capitalization of $2.84 billion, a PE ratio of -4.75 and a beta of 0.85. The firm has a fifty day simple moving average of $6.91 and a 200-day simple moving average of $7.02. Recursion Pharmaceuticals has a one year low of $5.60 and a one year high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the business earned ($0.43) EPS. The company's revenue for the quarter was up 147.6% compared to the same quarter last year. As a group, sell-side analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $6.67, for a total transaction of $76,351.49. Following the completion of the sale, the director now directly owns 7,089,007 shares of the company's stock, valued at $47,283,676.69. This represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 55,341 shares of company stock valued at $393,490. 15.75% of the stock is owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in RXRX. Bank of New York Mellon Corp lifted its holdings in Recursion Pharmaceuticals by 20.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,060,804 shares of the company's stock worth $7,956,000 after purchasing an additional 178,994 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in Recursion Pharmaceuticals by 25.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 44,241 shares of the company's stock valued at $332,000 after buying an additional 9,058 shares during the last quarter. Rhumbline Advisers raised its holdings in Recursion Pharmaceuticals by 24.1% in the 2nd quarter. Rhumbline Advisers now owns 281,348 shares of the company's stock worth $2,110,000 after acquiring an additional 54,576 shares during the period. Victory Capital Management Inc. lifted its position in Recursion Pharmaceuticals by 13.5% during the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company's stock worth $164,000 after acquiring an additional 2,598 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in Recursion Pharmaceuticals by 11.1% during the second quarter. Arizona State Retirement System now owns 47,691 shares of the company's stock valued at $358,000 after acquiring an additional 4,760 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.